Inhibitory effect of 2, 3-diaryl-2H-1-benzopyran derivative on estrogen-induced uterine hyperplasia and endometrial cancer
2.3.1. Classification of endometrial cancer 18
2.3.2. Risk factors for endometrial cancer 20
2.3.3. Treatment options for endometrial cancer 22-23
   2.3.3.1. Surgery 22
   2.3.3.2. Radiation 22
   2.3.3.3. Hormonal Therapy 22
   2.3.3.4. Chemotherapy 22

2.4. Targeted Therapy for endometrial hyperplasia and endometrial cancer 24-43
   2.4.1. Estrogen receptor as target for endometrial hyperplasia and endometrial cancer therapy 25-38
      2.4.1.1. Estrogen receptor structure and function 25
      2.4.1.2. Estrogen receptor signaling and regulation of endometrial proliferation and carcinoma 26
         2.4.1.2.1. Classical Genomic pathway 27
         2.4.1.2.2. Non-Classical Genomic pathway 27
         2.4.1.2.3. Non Genomic pathway 28
      2.4.1.3. GPR30/EGFR/ERK signaling pathway 30
      2.4.1.4. Selective estrogen receptor modulators 32
      2.4.1.5. Pure antiestrogens 35
      2.4.1.6. Aromatase inhibitor 36
      2.4.1.7. Limitations and future perspectives of SERMs in endometrial hyperplasia and endometrial cancer therapy 37
   2.4.2. Wnt/b catenin as a target 39-43
      2.4.2.1. Wnt/β-catenin signaling 39
      2.4.2.2. Wnt/β-secretase inhibitors 41

3. Experimental studies
   3.1. Study 1 45-67
Inhibition of hyperplasia formation by 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo (b) pyran in rat uterus.

3.1.1. Introduction 46-47
3.1.2. Material & Methods 48-51
3.1.3. Results 52-64
- Effect of K-1 on uterine mass of overectomized rats 52
- Uterine histology and histomorphometry 52
- Effect on expression of proliferation markers PCNA and cyclinD1 54
- Expression of ERE & AP-1 regulated proteins & proto-oncogenes in rat uterus 55
- The quantitative mRNA expression of ER and PR 56
- Western blot analysis of proto-oncogenes 57
- Apoptosis inducing activity in uterine hyperplasia 58
- Akt survival pathway in uterine hyperplasia 59
- Cleavage of caspase-9, -3, and PARP 60
- Bax/Bcl-2 ratio 62
- Effect of K-1 treatment in ovariectomized rat uterus 63
3.1.4. Discussion 65-67

3.2. Study 2 68-96
Inhibitory effect of 2-(piperidinoethoxyphenyl)-3-(4-hydroxy phenyl) -2H-benzo (b) pyran (K-1) on human primary endometrial hyperplasia cells.

3.2.1. Introduction 69-70
3.2.2. Material & Methods 71-76
3.2.3. Results 77-92
- Effect of K-1 on endometrial hyperplasia cell proliferation 77
- Expression of proliferation markers and Wnt/β-catenin signaling markers in human endometrial hyperplasia cells 78
- Expression of β-catenin & its downstream effectors 80
3.2.4. Discussion

3.3. Study 3

Anti-tumorigenic action of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo (b) pyran in ishikawa xenograft.

3.3.1. Introduction

3.3.2. Material & Methods

3.3.3. Results

- Effect of compound K-1 on cell proliferation 104
- Effect of compound K-1 on the activation of EGFR in vitro and EGFR phosphorylation in xenograft tumor in vivo 104
- Effect of compound K-1 treatment on growth of xenograft tumor in mice 105
- Effect of compound K-1 treatment on Histomorphology of liver, lungs, spleen, uterus and kidney 108
- Effect of compound K-1 treatment on the expression of proliferation markers in xenograft tissue 109
- Effect of compound K-1 on MAPK signaling in xenograft tissue 110
• Effect of compound K-1 on expression of cell cycle regulatory genes in xenograft tissue 111
• Effect of compound K-1 on apoptosis in xenograft tissue 112
• Analysis of apoptotic markers 113
• Cytotoxicity effect of compound K-1 114

3.3.4. Discussion 116-118

4. Bibliography 119-145
5. Achievements 146-148

*********